For the week of Jan. 3-9, the U.S. Department of Health and Human Services reported nearly 200,000 shipments of monoclonal antibody drugs. Almost 50,000 were sotrovimab.

1st COVID drug hits the market. ... sotrovimab is the main monoclonal antibody used for patients experiencing mild or moderate symptoms because it has been found to be effective against omicron.

Casadevall said new monoclonal antibody drugs are still worth pursuing, since they have proven safe and effective against Covid. “I would not give up on something like this," he said.

This was the last monoclonal antibody drug authorized by the FDA to treat COVID-19. The decision was made because it is not expected to neutralize new Omicron subvariants.

In late November, the Food and Drug Administration revoked its emergency use authorization for bebtelovimab, a monoclonal antibody treatment for Covid-19, because it wasn’t effective against the ...

Researchers from the Netherlands and Japan have developed antibodies for the novel coronavirus that can neutralize the pathogen in labs. The drugs still need to prove their effectiveness in human ...

Monoclonal antibody drugs were the first tailor-made covid-19 treatment out of the gate, highly effective medicines that helped buy time before vaccines could be widely deployed.

A new type of coronavirus treatment might be ready even before the first vaccine candidates are approved. Monoclonal antibody therapies can be used to treat … ...

The drug, peresolimab, is a monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1), which serves as the brakes on the immune system, said study author Dr. Ajay Nirula.

Monoclonal antibody drugs were the first tailor-made COVID-19 treatment out of the gate, highly effective medicines that helped buy time before vaccines could be widely deployed.